(Q77933878)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10385779%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

title

Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10385779%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

author name string

D K Murdock

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10385779%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

A K Murdock

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10385779%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

R W Murdock

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10385779%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

K J Olson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10385779%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

A M Frane

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10385779%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

M E Kersten

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10385779%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

D M Joyce

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10385779%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

S E Gantner

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10385779%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

language of work or name

English

0 references

publication date

1 July 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10385779%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

published in

American Heart Journal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10385779%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

volume

138

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10385779%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

page(s)

151-155

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10385779%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

issue

1 Pt 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10385779%20AND%20SRC:MED&resulttype=core&format=json

Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators.

9 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Familial lipoprotein disorders in patients with premature coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Combination drug therapy for familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Rhabdomyolysis associated with simvastatin-gemfibrozil therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Rhabdomyolysis after taking atorvastatin with gemfibrozil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Safety of combined pravastatin-gemfibrozil therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970261-9

10.1016/S0002-8703(99)70261-9

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10385779%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

1 reference